Multiple Sclerosis (MS) Market – Trends Forecast Till 2030

Market Snapshot

Market Overview

The global Multiple Sclerosis (MS) market size was estimated at USD 25.2 billion in 2023 and is projected to reach USD 34.9 billion in 2030 at a CAGR of 4.76% during the forecast period 2023-2030.

Multiple sclerosis is a chronic inflammatory disease that causes demyelination, cutting of axons and degeneration of neurons in the brain and spinal cord. The body's immune system targets neurons in the central nervous system and damages the myelin sheath. It is a potentially debilitating disease that causes disturbances in the body's communication and coordination. Symptoms of multiple sclerosis vary greatly depending on the extent of the damage and the number of neurons affected. Some of the observed symptoms include fatigue, numbness, spasticity, bladder dysfunction, cognitive changes, emotional changes and depression. A person with severe MS has speech and movement problems. Multiple sclerosis can be divided into four types: RRMS, SPMS, PPMS and PRMS.

The growth is due to the fact that major market players have invested in R&D to develop innovative medicines. For example, in December 2020, Adamas Pharmaceuticals Inc. announced Results of a phase 3 clinical trial of amantadine ADS-5102 for the treatment of MS patients. Product launches, increasing government initiatives to improve access to treatment and care, and increasing prevalence of multiple sclerosis are expected to drive global market expansion.

On the other hand, high cost of drugs may hamper the market growth to some extent.

The emergence of COVID-19 slowed the demand for multiple sclerosis drugs due to lower patient volumes going for the disease diagnosis and delays in treatment processes. Key players in the market experienced slow growth in their revenues due to the COVID-19 pandemic. The reallocation of healthcare resources for COVID-19 treatment, fewer people going for the disease diagnosis, and supply chain disruptions impacted the sales of these drugs for the treatment of MS.

Delvens Industry Expert's Standpoint

The pandemic had a considerable impact on businesses globally, with nations like India and China bearing the brunt of the virus's outbreak. The growth of the multiple sclerosis drug market is supported by government and non-governmental organization support. The government and non-governmental organizations fund several schemes and programs to offer their support to improve the quality of life of people with multiple sclerosis. Companies are rapidly increasing their efforts to focus on new products to meet the growing demand for MS drugs. Multiple sclerosis requires lifelong treatment, which increases the overall cost of patient care. In order to provide better and more effective treatments for multiple sclerosis in the market, companies are developing specific drugs for the treatment of multiple sclerosis.In addition, some notable changes in recent past for the treatment of the RRMS, and continuous drug development for treating multiple sclerosis is also expected to aid the growth in this market. These factors have led to the expansion of the market and increased demand for Multiple Sclerosis (MS) solutions.

Market Portfolio

Key Findings

• The Drug Class segment is further fragmented into Immunomodulators, Immunosuppressants, Interferons and others. The immunomodulators segment is expected to account for a larger market size during the forecast period. Higher prescription rates, brand loyalty, and the presence of a wide range of drug alternatives are some key drivers attributing to its largest share.

• The Distribution Channel segment is further bifurcated into Hospital Pharmacy, Retail Pharmacy, Online Pharmacy and Others. The Hospital Pharmacy is the largest market during the forecast period. owing to favorable health reimbursement and increased government efforts to strengthen the government hospital pharmacies. Moreover, the online pharmacy segment is poised to experience lucrative growth due to the increasing number of online portals distributing prescription drugs across the globe. Moreover, due to the outbreak of COVID-19, lockdown restrictions were imposed globally to control the spread of the virus. This increased the need for home delivery of medicines, thereby spurring segmental growth.

• The Route of Administration segment is further bifurcated Oral, Parenteral and Others. Oral Route of Administration to account for a larger market size during the forecast period. Classical multiple sclerosis (MS) treatments using first-line injectable drugs, despite being widely applied, remain a foremost concern regarding therapeutic adherence and efficacy. Novel oral drugs recently approved for treating MS represent significant advances in therapy. The oral route of administration supports patient satisfaction and increases therapeutic compliance.
   
• The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America is estimated to account for the largest market share during the forecast period owing to the growing prevalence of multiple sclerosis.

Regional Analysis

North America to Dominate the Market

• North America is estimated to account for the largest market share during the forecast period. In North America, there is growing prevalence of multiple sclerosis.
   
• Moreover, growing focus of major key players on novel technology will further propel the market’s growth rate in this region.

Competitive Landscape

• Abbott
• AbbVie Inc.
• Acorda Therapeutics Inc.
• Actelion Pharmaceuticals Ltd
• Allergan
• AstraZeneca
• Bayer AG
• Biogen Inc.
• Bristol-Myers Squibb Company
• Cipla Inc. 
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Genentech, Inc.
• GlaxoSmithKline plc
• Johnson & Johnson
• Merck & Co., Inc.
• Mylan N.V.
• Novartis AG
• Opexa Therapeutics, Inc.
• Pfizer Inc.
• Sanofi S. A.
• Teva Pharmaceuticals

Recent Developments

• In June 2022, Sandoz expands its portfolio with the launch of the generic drug Dimethyl fumarate HEXAL, which is approved for the treatment of adults with relapsing-remitting multiple sclerosis (RRMS) in Germany.
   
• In February 2022, Teva Pharmaceuticals Europe BV confirmed that the SmPC for COPAXONE (Glatiramer Acetate (GA) injection) 20mg/mL and 40mg/mL, indicated for the treatment of relapsing forms of multiple sclerosis (RMS) in Europe, has been updated.

Reasons to Acquire

• Increase your understanding of the market for identifying the most suitable strategies and decisions based on sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends, and factors.
   
• Gain authentic and granular data access for the Multiple Sclerosis (MS) Market to understand the trends and the factors involved in changing market situations.
   
• Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future.
   
• In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns.

Report Scope